Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
About ACHIEVE-1 and ACHIEVE clinical trial program ACHIEVE-1 (NCT05971940) is a Phase 3, 40-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron 3 mg, 12 mg and 36 mg as monotherapy to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone
With the advent of human embryonic stem cells and human induced pluripotent stem cells (hiPSCs), the production of cardiomyocytes with a purity exceeding 90% has become feasible
Coverage options are available through United Healthcare, Cigna, Blue Cross Blue Shield, Aetna, among others
Subcutaneous Injection Injectable GHK-Cu bypasses the skin barrier entirely
